Prabhudas Lilladher Remains a Sell on Deepak Nitrite Limited (DEEPAKNTR)
Prabhudas Lilladher analyst maintained a Sell rating on Deepak Nitrite Limited (DEEPAKNTR – Research Report) yesterday and set a price target of INR1,799.00. The company's shares closed last Friday at INR2,027.30.
Confident Investing Starts Here:
The analyst consensus on Deepak Nitrite Limited is currently a Hold rating.
Based on Deepak Nitrite Limited's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of INR21.67 billion and a net profit of INR2.03 billion. In comparison, last year the company earned a revenue of INR17.68 billion and had a net profit of INR1.5 billion
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 hours ago
- Yahoo
JPMorgan Backs RIL Despite Margin Pressures
On Thursday, analysts at JPMorgan reaffirmed their Overweight rating on Reliance Global Group, Inc. (NASDAQ:RELI), while raising the price target to INR1,568 from INR1,530, representing an upside of over 8% from the current levels. In their analysis, the analysts cited that although refining and petrochemical margins have dropped, the downside risk is likely to remain modest throughout the year. An insurance agent talking to a customer in their home office about healthcare insurance options. Having said that, the one-third contribution of the oil-to-chemical (O2C) segment means that there will only be a marginal impact on the consolidated EBITDA. Additionally, the Retail and Telecom segments are anticipated growth catalysts for Reliance Global Group, Inc. (NASDAQ:RELI), driven by favorable base influences. With the Spetner's Associates acquisition completion, the management believes that the strategic traction will accelerate the company's market footprint and expand the agency network. This improvement through synergies and other unanticipated positive factors could translate to higher margins and cost savings. The optimism surrounding EBITDA from the Telecom and Retail sectors can also not be overlooked. Reliance Global Group, Inc. (NASDAQ:RELI) is an InsurTech company that emphasizes acquiring and managing wholesale and retail insurance agencies across the United States. Founded in 2013, the giant leverages technology to transition from the conventional insurance agency model. While we acknowledge the potential of RELI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure. None.
Yahoo
20 hours ago
- Yahoo
HSBC Upgrades Dr. Reddy's Laboratories Limited (RDY) to Buy from Hold
On June 5, HSBC upgraded Dr. Reddy's Laboratories Limited (NYSE:RDY) from Buy to Hold, raising the price target to INR1,445 from INR1,235, citing an optimistic outlook for the company in terms of earnings potential and solid market standing. A worker at a biopharmaceutical facility packaging an active pharmaceutical ingredient. HSBC's updated estimates for FY2026 to FY2028 take into account the shifting market tide for semaglutide and gRevlimid. The analysts are waiting for semaglutide to be introduced in Canada, Brazil, and India at the beginning of FY2027, which is a greater leap from their prior hypothesis of a launch only in Canada by Q4 of FY2026. The analysts revised their FY2026 sales figures for Dr. Reddy's Laboratories Limited (NYSE:RDY)'s gRevlimid, noting the growing competition. The adjustment includes a 5.1% decrease in the EPS estimate for FY2026, while the EPS forecast for FY2027 and FY2028 grew by 12% to 13%. According to HSBC analysts, the expected surge in semaglutide sales will strengthen Dr. Reddy's earnings. HSBC assigned a new price target for RDY's American Depositary Receipts (ADR) as well, raising it from $14.44 to $16.90. Dr. Reddy's Laboratories Limited (NYSE:RDY) is a global pharma company based in Hyderabad, India, that makes both branded and generic medicines for a wide range of health conditions. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. While we acknowledge the potential of RDY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
5 days ago
- Business Insider
Morgan Stanley Remains a Buy on Prestige Estates Projects Limited (PRESTIGE)
Morgan Stanley analyst Praveen Choudhary maintained a Buy rating on Prestige Estates Projects Limited (PRESTIGE – Research Report) on May 30 and set a price target of INR1,700.00. The company's shares closed last Friday at INR1,484.00. Confident Investing Starts Here: According to TipRanks, Choudhary is a 3-star analyst with an average return of 1.8% and a 49.15% success rate. Choudhary covers the Consumer Cyclical sector, focusing on stocks such as Melco Resorts & Entertainment, Galaxy Entertainment Group, and Wynn Macau. Currently, the analyst consensus on Prestige Estates Projects Limited is a Moderate Buy with an average price target of INR1,825.00, implying a 22.98% upside from current levels. In a report released on May 31, Jefferies also maintained a Buy rating on the stock with a INR1,700.00 price target. Based on Prestige Estates Projects Limited's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of INR20.25 billion and a net profit of INR2.33 billion. In comparison, last year the company earned a revenue of INR16.81 billion and had a net profit of INR2.67 billion
